POTIGA Trademark

Trademark Overview

On Wednesday, March 12, 2008, a trademark application was filed for POTIGA with the United States Patent and Trademark Office. The USPTO has given the POTIGA trademark a serial number of 77420484. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, November 28, 2011. This trademark is owned by Valeant Pharmaceuticals North America. The POTIGA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of epilepsy, seizures and neurological disorders; potassium preparations for pharmaceuticals
potiga

General Information

Serial Number77420484
Word MarkPOTIGA
Filing DateWednesday, March 12, 2008
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, November 28, 2011
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 5, 2008

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of epilepsy, seizures and neurological disorders; potassium preparations for pharmaceuticals

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, March 19, 2008
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameValeant Pharmaceuticals North America
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIrvine, CA 92618
Party NameValeant Pharmaceuticals North America
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressAliso Viejo, CA 92656

Trademark Events

Event DateEvent Description
Wednesday, January 21, 2015ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Monday, November 28, 2011ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, November 28, 2011ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 20, 2011ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, April 27, 2011ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Tuesday, April 26, 2011NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, April 25, 2011EXTENSION 5 GRANTED
Friday, April 22, 2011EXTENSION 5 FILED
Friday, April 22, 2011TEAS EXTENSION RECEIVED
Wednesday, March 23, 2011ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, November 3, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, November 2, 2010EXTENSION 4 GRANTED
Monday, October 25, 2010EXTENSION 4 FILED
Monday, October 25, 2010TEAS EXTENSION RECEIVED
Friday, May 14, 2010NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 13, 2010EXTENSION 3 GRANTED
Tuesday, April 20, 2010EXTENSION 3 FILED
Tuesday, May 11, 2010CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, April 20, 2010TEAS EXTENSION RECEIVED
Thursday, October 8, 2009EXTENSION 2 GRANTED
Tuesday, October 6, 2009EXTENSION 2 FILED
Tuesday, October 6, 2009TEAS EXTENSION RECEIVED
Monday, May 11, 2009EXTENSION 1 GRANTED
Wednesday, April 22, 2009EXTENSION 1 FILED
Monday, May 11, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, April 22, 2009TEAS EXTENSION RECEIVED
Tuesday, October 28, 2008NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 5, 2008PUBLISHED FOR OPPOSITION
Wednesday, July 16, 2008NOTICE OF PUBLICATION
Friday, June 27, 2008LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, June 27, 2008ASSIGNED TO LIE
Friday, June 27, 2008APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, June 19, 2008ASSIGNED TO EXAMINER
Wednesday, March 19, 2008NEW APPLICATION ENTERED IN TRAM

Related Keywords

potiga preparations disorders potassium pharmaceuticals neurological seizures treatment epilepsy pharmaceutical